DBD vs AGYS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 02, 2026

DBD

50.4
AI Score
VS
AGYS Wins

AGYS

55.1
AI Score

Investment Advisor Scores

DBD

50score
Recommendation
HOLD

AGYS

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DBD AGYS Winner
Revenue 1.82B 87.68M DBD
Net Income 20.50M 8.99M DBD
Gross Margin 24.8% 63.5% AGYS
Net Margin 1.1% 10.3% AGYS
Operating Income 90.00M 9.74M DBD
ROE 2.1% 2.7% AGYS
ROA 0.5% 1.9% AGYS
Total Assets 3.74B 472.85M DBD
Current Ratio 1.27 1.74 AGYS

Relative Price Performance (Last 90 Days)

DBD 1M: -11.7% · 3M: -4.2% AGYS 1M: -3.4% · 3M: +64.2%

Current Technical Phase

DBD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 33

RSI (14): 32.9 · Price: $73.59

AGYS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (18.6% over 20 days), RSI 53

RSI (14): 53.1 · Price: $105.16

Fundamentals Snapshot

Metric DBD AGYS
Market Cap
Forward P/E 10.5 48.4
Trailing P/E 24.9 74.8
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin 0.3% 0.6%
Operating Margin 0.1% 0.1%
EPS 2.86 1.44
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, AGYS is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.